Access to high-cost drugs for rare diseases in Brazil: mucopolysaccharidosis Type I

被引：0
|
作者：
Boy, R. [1 ,2 ]
Krug, B. [3 ]
Gialdi, O. [4 ]
Santana-da-Silva, L. C. [5 ]
Steiner, C. [6 ]
Acosta, A. X. [7 ]
Ribeiro, E. M. [8 ]
Galera, M. F. [9 ]
Leivas, P. G. C. [10 ]
Braz, M. [2 ]
Schwartz, I. V. [3 ,11 ]
机构：
[1] Univ Estado Rio De Janeiro, HUPE, Dept Pediat, Rio De Janeiro, Brazil
[2] UNIGRANRIO, Clin Genet Serv, Duque De Caxias, Brazil
[3] HCPA, Med Genet Serv, Porto Alegre, RS, Brazil
[4] Minist Hlth, Brasilia, DF, Brazil
[5] UFPA, Inborn Errors Metab Lab, Maringa, Parana, Brazil
[6] Univ Estadual Campinas, Dept Med Genet, Campinas, SP, Brazil
[7] Univ Fed Bahia, Dept Pediat, Salvador, BA, Brazil
[8] HIAS, Fortaleza, Ceara, Brazil
[9] Univ Cuiaba, Med Genet & Mol Biol Unit, Cuiaba, Mato Grosso, Brazil
[10] UFGRS, Sch Law, Porto Alegre, RS, Brazil
[11] Univ Fed Rio Grande do Sul, Dept Genet & Mol Biol, Porto Alegre, RS, Brazil
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2010年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] Access to high-cost drugs in Brazil from the perspective of physicians, pharmacists and patients
    Mattozo Rover, Marina Raijche
    Vargas-Pelaez, Claudia Marcela
    Farias, Mareni Rocha
    Leite, Silvana Nair
    [J]. GACETA SANITARIA, 2016, 30 (02) : 110 - 116
  • [2] Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
    Boy, Raquel
    Schwartz, Ida V. D.
    Krug, Barbara C.
    Santana-da-Silva, Luiz C.
    Steiner, Carlos E.
    Acosta, Angelina X.
    Ribeiro, Erlane M.
    Galera, Marcial F.
    Leivas, Paulo G. C.
    Braz, Marlene
    [J]. JOURNAL OF MEDICAL ETHICS, 2011, 37 (04) : 233 - 239
  • [3] GLOBAL TRENDS IN ALTERNATIVE ACCESS ARRANGEMENTS FOR HIGH-COST ONCOLOGY AND RARE DISEASE DRUGS
    Nash, C.
    Kunitskaya, A.
    Duttagupta, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S252 - S252
  • [4] HIGH-COST ONCOLOGY DRUGS IN BRAZIL AND MEXICO: ACCESS DIFFERENCES BETWEEN THE PUBLIC AND PRIVATE SETTINGS
    Anilines, Giao N. T.
    Ribeiro, A.
    Duval, A.
    Moore, R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A879 - A879
  • [5] High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders
    de Souza, Monica Vinhas
    Krug, Barbara Correa
    Picon, Paulo Dornelles
    Doederlein Schwartz, Ida Vanessa
    [J]. CIENCIA & SAUDE COLETIVA, 2010, 15 : 3443 - 3454
  • [6] High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study
    Manea, Silvia
    Dalla Pozza, Laura Visona
    Minichiello, Cinzia
    Altieri, Linda
    Mazzucato, Monica
    Bonin, Mauro
    De Ambrosis, Paola
    Borgonovi, Elio
    Facchin, Paola
    [J]. HEALTH SERVICES MANAGEMENT RESEARCH, 2024, 37 (01) : 52 - 60
  • [7] Serious adverse events with high-cost drugs accessed through litigation in Brazil
    da Silva, Ricardo Eccard
    Lima, Elisangela da Costa
    Novaes, Maria Rita C. G.
    Serpa Osorio-de-Castro, Claudia Garcia
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 159 - 159
  • [8] OPPORTUNITIES FOR HIGH-COST DRUGS IN INDIA
    Ramabadran, A.
    Samuel, J. J.
    Edathodu, A.
    Mukku, S. R.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A131 - A131
  • [9] Improving access to high-cost cancer drugs in Latin America: Much to be done
    Ruiz, Rossana
    Strasser-Weippl, Kathrin
    Touya, Diego
    Herrero Vincent, Carmen
    Hernandez-Blanquisett, Abraham
    St Louis, Jessica
    Bukowski, Alexandra
    Goss, Paul E.
    [J]. CANCER, 2017, 123 (08) : 1313 - 1323
  • [10] IMPACT OF HEALTH TECHNOLOGY ASSESSMENT IN LITIGATION CONCERNING ACCESS TO HIGH-COST DRUGS
    Aleman, Alicia
    Galan, Ana Perez
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (04) : 411 - 414
12345